News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
CellGenix GmbH has started expanding its cell and gene therapy reagents facility in Freiburg, Germany citing the progression of customer projects into clinical development and commercial launch.
Cambridge Research Biochemicals (CRB) has launched a second catalogue of research antibodies for academia, pharma and outsourcing firms.
Abzena Plc has been contracted to make an antibody drug candidate for wet age-related macular degeneration by developers at University College London.
Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.